Yoshiyuki
Hattori, PhD
Hoshi University, Department of Molecular Pharmaceutics, Professor
Email: yhattori＠hoshi.ac.jp
ORCiD ResearchGate
Google
Scholar Scopus
(Research Interest)
Development
of drug delivery system for nucleic acid-based therapeutics
Nucleic acid (RNA)-based therapeutics involve
the use of coding RNA, such as messenger RNA (mRNA), as well as non-coding RNA,
such as small interfering RNA (siRNA). siRNAs are synthetic RNA duplexes of
21–23 base pairs in length that are designed to specifically target a
particular mRNA for degradation. siRNA therapeutics can knock down the
expression of target genes in the cells through a phenomenon known as RNA
interference (RNAi). In contrast, messenger RNA (mRNA) therapeutics enable the
immediate and efficient expression of therapeutic proteins in cells. Therefore,
RNA-based therapeutics have become an increasingly important strategy for
treating a variety of human diseases, such as cancer. However, both siRNA and
mRNA cannot diffuse through cellular membranes owing to their hydrophilic
nature and negative charges, and are susceptible to enzymatic degradation by
serum endonucleases; therefore, delivery systems of RNA-based therapeutics to
the cells are needed. In our laboratory, we are developing lipid-based
nanoparticles for efficient delivery of siRNA and mRNA therapeutics to target
tissues without side effects.
(Awards)
(Grants)
2024-2026:
Grant-in-Aid for Scientific Research (C),
Japan Society for the Promotion of
Science (KAKENHI Grant Number 24K09899)
Principal
investigator “Development of mRNA lipid nanoparticles for tumor vaccine”
2020-2022:
Grant-in-Aid for Scientific Research (C),
Japan Society for the Promotion of
Science (KAKENHI Grant Number 20K07142)
Principal
investigator “Development of folate-modified siRNA lipoplexes for
tumor-targeting by intravenous injection”
2017-2019:
Grant-in-Aid for Scientific Research (C),
Japan Society for the Promotion of
Science (KAKENHI Grant Number 17K08251)
Principal
investigator “Development of siRNA therapy for liver metastasis by sequential
injection of chondroitin sulfate and siRNA lipoplex”
2014-2016:
Grant-in-Aid for Scientific Research (C),
Japan Society for the Promotion of
Science (KAKENHI Grant Number 26460046)
Principal
investigator “siRNA delivery to cancer tissue by sequential injection of
anionic polymer and siRNA lipoplex”
2012-2014:
Science Research Promotion Fund from the
Promotion and Mutual Aid Corporation for Private Schools of Japan
Co-investigator
“Advanced drug discovery research on dyslipidemia treatment targeting visceral
fat”
2012:
a3 program, Astellas Pharma
Inc. Japan
Principal
investigator, “Development of lipid-based nanoparticle for siRNA delivery to
the central nervous system and tumor with high gene silencing effect and
safety”
2012-2013: Advanced Research for Medical Products
Mining Programme of the National Institute of
Biomedical Innovation (NIBIO), Japan,
Co-investigator
“Development of delivery system of nucleic acid-based medicine against
refractory cancer resistant to endocrine therapy”
2012-2015:
Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science
(KAKENHI Grant Number 24590152)
Co-investigator
“Development of PEGylated Histone Deacetylase Inhibitor Having Prolonged Blood
Retention and EPR effect”
2011-2013:
Grant-in-Aid for Young Scientists (B),
Japan Society for the Promotion of Science (KAKENHI Grant Number 23790203)
Principal
investigator “Evaluation of antitumor effect by injection of tumor-associated
macrophage-targeting liposomes”
2009-2011:
Grant-in-Aid for Scientific Research
(C), Japan Society for the Promotion of Science (KAKENHI Grant Number
21590131)
Co-investigator
“Development of cationic histone deacetylase inhibitors as enhancer of gene
transfection and expression”
2008-2010:
Grant-in-Aid for Young Scientists (B),
Japan Society for the Promotion of Science (KAKENHI Grant Number 20790146)
Principal
investigator “Angiotensin II-induced hypertension enhanced delivery of
liposomal anti-cancer drugs into tumor”
2007-2008:
Grant-in-Aid for Scientific Research
(C), Japan Society for the Promotion of Science (KAKENHI Grant Number
19590110)
Co-investigator
“Synthesis of histone deacetylase inhibitors for development of drug delivery”
2006-2007:
Grant-in-Aid for Young Scientists (B),
Japan Society for the Promotion of Science (KAKENHI Grant Number 18790691)
Principal
investigator “Development of inflammation-targeting vectors of decoy oligonucleic acid for inflammatory disease therapy”
2004-2005:
Grant-in-Aid for Young Scientists (B),
Japan Society for the Promotion of Science (KAKENHI Grant Number 16790113)
Principal
investigator “Development of folate-modified lipid-based nanoparticles for
suicide gene therapy to prostate cancer”
(Publications) * Corresponding author
(135)
Y. Hattori*, H. Kawasaki, M. Nishiyama, M. Shinkawa, and K. Kawano,
Effect of cationic amphiphilic drugs on mRNA lipoplex-induced protein
expression, Journal
of Liposome Research, in
press. [Pubmed] [Link]
(134)
K. Kawano and Y. Hattori, Evaluation of anionic polymer-coated siRNA
lipoplexes prepared using a modified ethanol injection method, Biomedical Reports, 24(3): 33 (2026). [Pubmed] [Link]
(133)
Y. Hattori*, A. Kurihara, and M. Shinkawa, Assessment of anionic siRNA
lipoplexes prepared via modified ethanol injection for tumor cell delivery, Biomedical Reports, 24(1): 12 (2026). [Pubmed] [Link]
(132)
R. Shimizu and Y. Hattori*, Effects of disaccharide and cationic lipid
types on reverse transfection with lyophilized mRNA lipoplexes, Experimental and Therapeutic
Medicine, 30(6): 239 (2025). [Pubmed] [Link]
(131)
Y. Hattori*, M. Shinkawa, A. Kurihara, and R. Shimizu, Optimization of
PEGylation for cationic triacyl lipid-based siRNA lipoplexes prepared using the
modified ethanol injection method for tumor therapy, Journal of Liposome Research, 35(3):
300-311 (2025). [Pubmed]
[Link]
(130)
Y. Ofuchi, H. Setoyama, T.
Miyoshi, K. Kawano, Y. Hattori, Y. Obata, Effect of alcohols on the skin
permeation of various drugs, Chemical and Pharmaceutical Bulletin, 73(4): 291-297 (2025). [Open
access] [Pubmed]
(129)
Y. Hattori* and R. Shimizu, Effective mRNA transfection of tumor cells
using cationic triacyl lipid-based mRNA lipoplexes, Biomedical Reports,
22(2): 25 (2025). [Open
access] [Pubmed]
(128)
Y. Hattori* and M. Tang, Effect of cationic and neutral lipids in
cationic liposomes on antibody production induced by systemic administration of
mRNA lipoplexes into mice, Journal of Drug Delivery Science and Technology,
100: 106034 (2024). [Scopus] [Link]
(127)
Y. Hattori*, M. Tang, H. Suzuki, A. Hattori, S. Endo, A. Ishii, A. Aoki,
M. Ezaki, and H. Sakai, Optimization of transfection into cultured cells with
siRNA lipoplexes prepared using a modified ethanol injection method, Journal
of Drug Delivery Science and Technology, 99: 106000 (2024). [Scopus]
[Link]
(126)
Y. Hattori*, M. Tang, J. Sato, M. Tsuiji, K.
Kawano, Evaluation of mRNA lipoplexes prepared using modified ethanol injection
method as a tumour vaccine, Journal of Drug
Targeting, 32(10): 1267-1277 (2024). [Link]
[Pubmed]
(125)
M. Tang, and Y. Hattori*, Effect of vorinostat
on protein expression in vitro and in vivo following mRNA lipoplex
administration, Biomedical Reports, 21(1): 105 (2024). [Pubmed] [Open
access]
(124)
A. Miatmoko, D. M. Cahyani, K. Kawano, Y. Hattori,
Comparative cellular and in vivo
anti-cancer studies of doxorubicin liposomes prepared with different types of
phospholipids, Indonesian Journal of Pharmacy, 35(3): 459-466 (2024). [Scopus] [Link]
(123)
Y. Hattori*, M. Tang, A. Aoki, M. Ezaki, H. Sakai, K. Ozaki, Effect of
the combination of cationic lipid and phospholipid on gene-knockdown using
siRNA lipoplexes in breast tumor cells and mouse lungs, Molecular Medicine
Reports, 28(4): 180 (2023). [Pubmed] [Open
access]
(122)
K. Kawano, A. Furuya, Y. Matsuda, C. Kimura, K. Yamaguchi, S. Wakabayashi, K.
Taniguchi, K. Ozaki, Y. Hattori, Preparation of liposomes
co-encapsulating doxorubicin and mifepristone for treating multidrug-resistant
cancer, Journal of Drug Delivery Science and Technology, 85: 104605
(2023). [Scopus]
[Link]
(121)
M. Tang, A. Sagawa, N. Inoue, S. Torii, K. Tomita, Y. Hattori*,
Efficient mRNA delivery with mRNA lipoplexes prepared using a modified ethanol
injection method, Pharmaceutics, 15(4): 1141 (2023). [Pubmed] [Open access]
(120)
M. Tang, S. Sakasai, H. Onishi, K. Kawano, Y.
Hattori*, Effect of PEG anchor in PEGylation of folate-modified cationic
liposomes with PEG-derivatives on systemic siRNA delivery into the tumor, Journal
of Drug Targeting, 31: 74-88 (2023). [Pubmed] [Link]
(119)
Y. Hattori*, H. Saito, K. Nakamura, A. Yamanaka, M. Tang, K. Ozaki, In
vitro and in vivo transfections using siRNA lipoplexes prepared by mixing
siRNAs with a lipid-ethanol solution, Journal of Drug Delivery Science and
Technology, 75: 103635 (2022). [Link].
(118)
Y. Hattori*, M. Tang, S. Torii, K. Tomita, A. Sagawa, N. Inoue, R.
Yamagishi, K. Ozaki, Optimal combination of cationic lipid and phospholipid in
cationic liposomes for gene knockdown in breast cancer cells and mouse lungs
using siRNA lipoplexes, Molecular Medicine Reports, 26(2): 253 (2022). [Pubmed] [Open
access]
(117)
M. Tang, Y. Hattori*, Effect of using amino acids in the freeze-drying
of siRNA lipoplexes on gene knockdown in cells after reverse transfection, Biomedical
Reports, 15(3): 72 (2021). [Pubmed] [Link]
(116)
Y. Hattori*, H. Saito, T. Oku, K. Ozaki, Effects of sterol derivatives
in cationic liposomes on biodistribution and gene knockdown in the lungs of
mice systemically injected with siRNA lipoplexes, Molecular Medicine Reports,
24(2): 598 (2021). [Pubmed] [Open
access]
(115)
H. Onishi, K. Mizuno, Y. Ikeuchi-Takahashi, Y. Hattori, Targeting
potential of alginate-glycyl-prednisolone conjugate nanogel to inflamed joints
in rats with adjuvant-induced arthritis, Journal of Drug Targeting,
29(8): 892-899 (2021). [Pubmed]
(114)
K. Mizuno, Y. Ikeuchi-Takahashi, Y. Hattori, H. Onishi, Preparation and
evaluation of conjugate nanogels of glycyl-prednisolone with natural anionic
polysaccharides as anti-arthritic delivery systems, Drug Delivery,
28(1): 144-152 (2021).
[Pubmed] [Open
access]
(113)
Y. Hattori*, K. Tamaki, S. Sakasai, K. Ozaki,
H. Onishi, Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro
gene-silencing effects and siRNA biodistribution in mice, Molecular Medicine
Reports, 22(5) 4183-4196 (2020). [Pubmed] [Open
access]
(112)
M. Tang, S. Hu, Y. Hattori*, Effect of pre-freezing and saccharide types
in freeze-drying of siRNA lipoplexes on gene-silencing effects in the cells by
reverse transfection, Molecular Medicine Reports, 22(4): 3233-3244
(2020). [Pubmed] [Open
access]
(111) Y. Hattori*, S.Hu, H. Onishi, Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-drying of siRNA lipoplexes on gene silencing in cells by reverse transfection, Journal of Liposome Research, 30(3): 235-245 (2020). [Pubmed]
(110)
H. Zhou, Y. Ikeuchi-Takahashi, Y. Hattori, H. Onishi,
Nanogels of a Succinylated Glycol Chitosan-Succinyl Prednisolone
Conjugate: Release Behavior, Gastrointestinal Distribution, and Systemic
Absorption, International Journal of
Molecular Sciences, 21(7): 2376 (2020). [Open access] [Pubmed]
(109)
Y. Hattori*, Y. Nakagawa, H. Onishi, Gene delivery into hepatic cells
with ternary complexes of plasmid DNA, cationic liposomes, and apolipoprotein
E-derived peptide, Experimental and Therapeutic Medicine, 18(4):
2628-2638 (2019). [Open
access] [Pubmed]
(108)
H. Zhou, A. Ichikawa, Y. Ikeuchi, Y. Hattori, H. Onishi, Nanogels of succinylated glycol chitosan-succinyl prednisolone
conjugate: preparation, in vitro characteristics and therapeutic potential, Pharmaceutics,
11(7): 333 (2019). [Pubmed] [Open access].
(107)
H. Onishi, Y. Ikeuchi-Takahashi, K. Kawano, Y. Hattori, Preparation of
chondroitin sulfate-glycyl-prednisolone conjugate nanogel and its efficacy in
rats with ulcerative colitis, Biological & Pharmaceutical Bulletin,
42(7): 1155-1163 (2019). [Pubmed]
(106)
Y. Hattori*, K. Tamaki, K. Ozaki, K. Kawano, H. Onishi, Optimized
combination of cationic lipids and neutral helper lipids in cationic liposomes
for siRNA delivery into the lung by intravenous injection of siRNA lipoplexes, Journal
of Drug Delivery Science and Technology, 52: 1042-1050 (2019). [Link]
(105)
Y. Hattori*, S. Shimizu, K. Ozaki, H. Onishi, Effect of cationic lipid
type in folate-PEG-modified cationic liposomes on folate receptor-mediated
siRNA transfection in tumor cells, Pharmaceutics, 11(4): 181 (2019). [Pubmed] [Open access]
(104)
Y. Hattori*, M. Nakamura, N. Takeuchi, K. Tamaki, K. Ozaki, H. Onishi,
Effect of cationic lipid type in PEGylated liposomes on siRNA delivery
following the intravenous injection of siRNA lipoplexes, World Academy of
Sciences Journal, 1(2): 74-85 (2019). [Link]
(103)
Y. Hattori*, M. Nakamura, N. Takeuchi, K. Tamaki, S. Shimizu, Y.
Yoshiike, M. Taguchi, H. Ohno, K. Ozaki, H. Onishi, Effect of cationic lipid in
cationic liposomes on siRNA delivery into the lung by intravenous injection of
cationic lipoplex, Journal of Drug Targeting, 27(2): 217-227 (2019). [Pubmed]
(102)
Y. Hattori*, N. Takeuchi, M. Nakamura, Y. Yoshiike, M. Taguchi, H. Ohno,
K. Ozaki, H. Onishi, Effect of cationic lipid type in cationic liposomes for
siRNA delivery into the liver by sequential injection of chondroitin sulfate
and cationic lipoplex, Journal of Drug Delivery Science and Technology,
48: 235-244 (2018). [Link]
(101)
Y. Hattori*, A. Nakamura, S. Hanaya, Y. Miyanabe,
Y. Yoshiike, T. Kikuchi, K. Ozaki, H. Onishi, Effect of chondroitin sulfate on
siRNA biodistribution and gene silencing effect in mice after injection of
siRNA lipoplexes, Journal of Drug Delivery Science and Technology, 41: 401-409 (2017). [Link]
(100)
Y. Hattori*, T. Kikuchi, K. Ozaki, H. Onishi, Evaluation of in vitro and
in vivo therapeutic anti-tumor efficacy of transduction of polo-like kinase 1
and heat shock transcription factor 1 small interfering RNA, Experimental
and Therapeutic Medicine, 14: 4300-4306 (2017). [Pubmed] [Open
access]
(99)
Y. Hattori*, T. Kikuchi, M. Nakamura, K. Ozaki, H. Onishi, Therapeutic
effects of protein kinase N3 small interfering RNA and doxorubicin combination
therapy on liver and lung metastases, Oncology Letters, 14: 5157-5166
(2017). [Pubmed] [Open
access]
(98) Y. Hattori*, Y. Machida, M. Honda, N. Takeuchi, Y. Yoshiike, H. Ohno, H. Onishi, Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes, Journal of Liposome Research, 27(4): 264-273 (2017). [Pubmed]
(97)
Y.
Hattori*,
Progress in the development of lipoplex and polyplex modified with anionic
polymer for efficient gene delivery, Journal
of Genetic Medicine and Gene Therapy,1: 3-18 (2017). [Link] [PDF]
(96)
H. Onishi, A. Fukasawa, A. Miatmoko,
K. Kawano, Y. Ikeuchi, Y. Hattori*, Preparation of chondroitin
sulfate-adipic acid dihydrazide-doxorubicin conjugate
and its antitumor characteristics against LLC cells, Journal of Drug
Targeting, 25(8): 747-753 (2017). [Pubmed]
(95)
Y. Hattori*, Y. Yoshiike, M. Honda, H. Ohno, H. Onishi, Evaluation of
small interfering RNA delivery into cells by reverse transfection in suspension
with cationic liposomes, Pharmacology & Pharmacy, 8: 129-139 (2017).
[Open
access]
(94)
K. Kawano, Y. Isoda, H. Toma, A. Fukasawa, E. Yonemochi, Y. Hattori, Effect of all-trans retinoic
acid-loaded liposomes on adipogenesis of obese mice, International Journal
of Pharmaceutical Sciences Research, 4: 121 (2017). [PDF]
(93) A. Miatmoko, K. Kawano, H. Yoda, E. Yonemochi, Y. Hattori*, Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent, Journal of Liposome Research, 27(2): 99-107 (2017). [Pubmed]
(92)
Y. Hattori*, Delivery of plasmid DNA into tumors by intravenous
injection of PEGylated cationic lipoplexes into tumor-bearing mice, Pharmacology
& Pharmacy, 7(7): 272-282 (2016). [Open
access]
(91)
Y. Hattori*, Y. Yoshiike, T. Kikuchi, N. Yamamoto, K. Ozaki, H. Onishi,
Evaluation of injection route of anionic polymer for siRNA delivery into the
liver by sequential injection of anionic polymer and cationic lipoplex of
siRNA, Journal of Drug Delivery Science and Technology, 35: 40-49
(2016). [Link]
(90) Y. Hattori*, S. Arai, T. Kikuchi, K. Ozaki, K. Kawano, E. Yonemochi, Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA, Journal of Drug Targeting, 24(4): 309–317 (2016). [Pubmed]
(89) K. Ishida, K. Taguchi, M.
Hida, S. Watanabe, K. Kawano, T. Matsumoto, Y. Hattori, and T.
Kobayashi, Circulating microparticles from diabetic rats impair endothelial
function and regulate endothelial protein expression, Acta Physiologica (Oxf),
216(2): 211-220 (2016). [Pubmed]
(88)
A. Miatmoko, K. Kawano, E. Yonemochi,
Y. Hattori*, Evaluation of cisplatin-loaded polymeric micelles and
hybrid nanoparticles containing poly(ethylene oxide)-block-poly(meth-acrylic
acid) on tumor delivery, Pharmacology & Pharmacy, 7(1): 1-8 (2016). [Open
access]
(87) Y. Hattori*, S. Arai, T. Kikuchi, M.
Hamada, R. Okamoto, Y. Machida, K. Kawano, Optimization of siRNA delivery
method into the liver by sequential injection of polyglutamic acid and cationic
lipoplex, Pharmacology & Pharmacy,
6 (7): 302-310 (2015). [Open
Acces]
(86) Y. Hattori*, K. Shibuya, K. Kojima, A. Miatmoko, K. Kawano, K. Ozaki, E. Yonemochi,
Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin, International Journal of Oncology, 47:
211-219 (2015). [Pubmed]
(85)
Y. Hattori*,
A. Nakamura, S. Arai, K. Kawano, Y. Maitani, E. Yonemochi, siRNA delivery to lung-metastasized tumor by
systemic injection with cationic liposome, Journal of Liposome Research,
25(4):
279-286 (2015). [Pubmed]
(84)
Y.
Hattori*,
J. Yamashita, C. Sakaida, K. Kawano, E. Yonemochi, Evaluation of Antitumor Effect of Zoledronic
Acid Entrapped in Folate-Linked Liposome for Targeting to Tumor-Associated
Macrophages, Journal of Liposome
Research, 25(2): 131-40 (2015). [Pubmed]
(83) Y. Hattori*, E. Hara, Y. Shingu, D. Minamiguchi, A. Nakamura, S. Arai, H. Ohno, K. Kawano, N. Fujii, E. Yonemochi, siRNA delivery into tumor cells by cationic cholesterol derivative-based nanoparticles and liposomes, Biological & Pharmaceutical Bulletin, 38: 30-38 (2015). [Pubmed]
(82) A. Miatmoko,
K. Kawano, Y. Hattori, Y. Maitani, E. Yonemochi, Evaluation of transfersome
and protransfersome for percutaneous delivery of
cisplatin in hairless mice, Journal of
Pharmaceutics & Pharmacology, S (1): 7 (2015). [Open
access]
(81) Y. Hattori*, S. Arai, R. Okamoto, M. Hamada, K. Kawano, E. Yonemochi,
Sequential intravenous injection of anionic polymer and cationic lipoplex of
siRNA could effectively deliver siRNA to the liver, International
Journal of Pharmaceutics, 476: 289-298 (2014). [Pubmed]
(80) Y. Hattori*, A. Nakamura, S. Arai, M. Nishigaki, H. Ohkura, K. Kawano, Y. Maitani and E. Yonemochi, In vivo siRNA delivery system for targeting to the liver by poly-L-glutamic acid-coated lipoplex, Results in Pharma Sciences, 4: 1-7 (2014). [Pubmed]
(79) Y. Hattori*, M. Date, S. Arai, K. Kawano, E. Yonemochi, Y. Maitani, Transdermal delivery of small interfering RNA with elastic cationic liposomes in mice, Journal of Pharmaceutics, Article ID 149695 (2013). [Pubmed] [Open Access]
(78) Y. Hattori*, H. Yamasaku, Y. Maitani, Anionic
polymer-coated lipoplex for safe gene delivery into tumor by
systemic injection, Journal of Drug Targeting, 21(7): 639-647 (2013). [Pubmed]
(77) K. Kawano#, Y.
Hattori#, H.
Iwakura, T. Akamizu, Y. Maitani, Combination therapy
with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with
adrenal neuroblastoma, Cancer Medicine, 2(3): 286–295 (2013). [Pubmed] #: Equal contribution
(76) Y. Hattori*, T. Nakamura, H, Ohno, N. Fujii, Y. Maitani, Enhanced
plasmid DNA transfer into tumor cells by nanoparticle composed of cholesteryl
triamine and diamine, Biological & Pharmaceutical Bulletin, 36: 856–860 (2013). [Pubmed]
(75) Y. Hattori*, T. Nakamura, H, Ohno, N. Fujii, Y. Maitani, siRNA
delivery for tumor by lipid-based nanoparticle composed
with hydroxyethylated cholesteryl triamine, International Journal of Pharmaceutics. 443: 221-229 (2013). [Pubmed]
(74) G.
Kamoshida, A. Matsuda, K. Katabami, T. Kato, H.
Mizuno, W. Sekine, T. Oku, S. Itoh, M. Tsuiji, Y. Hattori, Y. Maitani, T.
Tsuji, Involvement of transcription factor Ets-1 in the expression of the α3
integrin subunit gene. FEBS
Journal, 279: 4535-4546 (2012). [Pubmed]
(73) K. Kawano, Y. Hattori, H. Iwakura, T. Akamizu, Y. Maitani, Adrenal tumor volume in a genetically engineered mouse model of neuroblastoma determined by magnetic resonance imaging, Experimental and Therapeutic Medicine, 4: 61-64 (2012). [Pubmed]
(72) S. Kobayashi, Y. Hattori, H. Osakada, K. Toma, Y. Maitani, Y. Hiraoka, T. Haraguchi, Early entry
and deformation of macropinosomes correlates with
high efficiency of decaarginine-PEG-lipid-mediated
gene delivery, Journal of Gene Medicine, 14 (4): 262-271 (2012). [Pubmed]
(71) M. Kato, Y. Hattori*, M. Kubo and Y. Maitani, Collagenase-1 injection improved tumor distribution and
gene expression of cationic lipoplex, International Journal of Pharmaceutics
423(2):
428-434 (2012).
[Pubmed]
(70) Y. Hattori*, Y.
Nagaoka, M. Kubo, H. Yamasaku , Y. Ishii,
H. Okita , H. Nakano, S.
Uesato, Y. Maitani, Antitumor effect of liposomal
histone deacetylase inhibitor-lipid conjugates in vitro, Chemical and Pharmaceutical Bulletin, 59(11): 1386-1392 (2011). [Pubmed]
(69) T. Izumisawa, Y. Hattori*, M. Date, K. Toma, Y. Maitani, Cell line-dependent internalization pathways determine DNA transfection efficiency of decaarginine-PEG-lipid, International Journal of Pharmaceutics, 404: 264–270 (2011). [Pubmed]
(68) Y. Hattori*, H. Ubukata, K.
Kawano, Y. Maitani, Angiotensin II-induced hypertension
enhanced therapeutic efficacy of liposomal doxorubicin in
tumor-bearing mice, International Journal of Pharmaceutics, 403: 178-184 (2011). [Pubmed]
(67) Y.
Hattori and Y. Maitani, Folate-linked lipid-based
nanoparticle gene delivery to the tumor, Encyclopedia
of Nanoscience and Nanotechnology, Edited by H. S. Nalwa, American
Scientific Publishers, 14: 263-277 (2011).
(66) Y. Hattori*, N. Kanamoto, K. Kawano, H. Iwakura, M. Sone, M.Miura, A. Yasoda, N. Tamura, H. Arai, T. Akamizu, K. Nakao,
Y. Maitani, Molecular
characterization of tumors from a transgenic
mice adrenal tumor model:
Comparison with human pheochromocytoma, International
Journal of Oncology, 37: 695-705 (2010). [Pubmed]
(65) A. Hioki, A. Wakasugi,
K. Kawano, Y. Hattori, Y. Maitani, Development of an In Vitro Drug Release
Assay of PEGylated Liposome Using Bovine Serum Albumin and HighTemperature,
Biological & Pharmaceutical Bulletin,
33(9): 1466-1470 (2010) [Pubmed].
(64)
H. Poerwono, S. Sasaki, Y. Hattori, K.
Higashiyama, Efficient microwave-assisted prenylation of pinostrobin
and biological evaluation of its derivatives as antitumor agents, Bioorganic & Medicinal Chemistry
Letters, 20: 2086-2089 (2010). [Pubmed]
(63) Y. Hattori*, M. Hakoshima, K. Koga and Y. Maitani,
Increase of therapeutic effect by treating nasopharyngeal tumor with
combination of HER-2 siRNA and paclitaxel, International
Journal of Oncology, 36: 1039-1046 (2010).
[Pubmed]
(62) K. Koga
, Y. Hattori*, M. Komori, R. Narishima, M. Yamasaki, M. Hakoshima, T. Fukui and
Y. Maitani,
Combination of RET siRNA and irinotecan inhibited the growth of medullary
thyroid carcinoma TT cells and xenografts via apoptosis, Cancer Science, 101: 941-947 (2010). [Pubmed]
(61) K. Goto, Y. Chiba,
K. Matsusue, Y. Hattori, Y. Maitani, H. Sakai, S. Kimura, M. Misawa, The proximal STAT6
and NF-kappaB sites are responsible for IL-13- and
TNF-alpha-induced RhoA transcriptions in human bronchial smooth muscle cells. Pharmacological
Research,
61: 466-472 (2010). [Pubmed]
(60) H. Ma,
K. Shiraishi, T. Minowa, K. Kawano, M. Yokoyama, Y. Hattori, Y. Maitani, Accelerated blood clearance was not induced for a
gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice, Pharmaceutical Research, 27(2):296-302 (2010). [Pubmed]
(59) Y.
Hattori, Cationic Cholesterol Derivative-Based
Nanoparticles for Cancer Gene Therapy, The Proceedings of Hoshi University, 52: 1-8 (2010). [Link]
(58) Y.
Hattori*, Development of Non-Viral Vector for Cancer Gene
Therapy, Yakugaku Zasshi, 130(7): 917-923 (2010). [Pubmed]
(57)
T.
Minowa, K. Kawano, H. Kuribayashi, K. Shiraishi, T. Sugino, Y. Hattori,
M. Yokoyama, Y. Maitani, Increase in tumour permeability following TGF-β type I receptor inhibitor treatment
observed by dynamic contrast-enhanced MRI. British
Journal of Cancer, 101(11): 1884-1890 (2009). [Pubmed]
(56) Y. Ishii, Y. Hattori, T. Yamada, S. Uesato, Y. Maitani, Y. Nagaoka, Histone
Deacetylase Inhibitor Prodrugs in Nanoparticle Vector Enhanced Gene Expression
In Human Cancer Cells. European
Journal of Medicinal Chemistry, 44: 4603-4610 (2009). [Pubmed]
(55) Y. Chiba, S. Onoda, Y. Hattori, Y. Maitani,
H. Sakai, and M. Misawa. Upregulation of ADAM8 in the
Airways of Mice with Allergic Bronchial Asthma. Lung, 187:
179-185 (2009). [Pubmed]
(54) Y. Hattori*, L. Shi, W.
Ding, K. Koga, K. Kawano, M. Hakoshima, Y. Maitani, Novel irinotecan-loaded liposome using phytic acid
with high therapeutic efficacy for colon tumors, Journal of Controlled Release, 136: 30-37 (2009). [Pubmed]
(53) Y. Hattori*, K. Koga, T. Izumisawa, M. Yamasaki, R. Narishima, S. Yoshida, T. Fukui and Y. Maitani, The distribution of mRNA expression and protein after
hydrodynamic injection of transgene in mice, Biological & Pharmaceutical Bulletin,
32(4): 755-759 (2009). [Pubmed]
(52) M. Furuhata, T. Izumisawa,
H. Kawakami, K. Toma, Y. Hattori, Y. Maitani, Decaarginine-PEG-liposome Enhanced Transfection Efficiency
and Function of Arginine Length and PEG, International Journal of Pharmaceutics, 37(1-2): 40-46 (2009). [Pubmed]
(51) W. Ding, T. Izumisawa,
Y. Hattori, X. Qi, D. Kitamoto, Y. Maitani, Non-ionic surfactant modified cationic liposomes
mediated gene transfection in vitro and in the mouse lung, Biological & Pharmaceutical Bulletin, 32(2): 311-315 (2009). [Pubmed]
(50) K. Kawano, E. Onose, Y. Hattori, Y. Maitani, Higher liposomal membrane fluidity enhances
the in vitro anti-tumor activity of folate-targeted liposomal mitoxantrone, Molecular Pharmaceutics, 6(1):
98-104 (2009). [Pubmed]
(49) W. Ding, Y. Hattori, X. Qi, D.
Kitamoto, Y. Maitani,
Surface properties of lipoplexes modified with MEL-A and Tween 80, Chemical and Pharmaceutical Bulletin, 57(2): 138-143 (2009). [Pubmed]
(48) T. Fujita, M. Furuhata, Y. Hattori,
H. Kawakami, K. Toma, Y. Maitani, Calcium enhanced delivery of tetraarginine-PEG-lipid-coated DNA/protamine complexes, International
Journal of Pharmaceutics,
368: 186-192 (2009).
[Pubmed]
(47) Y. Maitani
and Y. Hattori, Oligoarginine-PEG-lipid particles for gene delivery. Expert Opinion on Drug Delivery, 6(10): 1065-1077
(2009). [Pubmed]
(46) Y. Hattori*, T. Yoshizawa, K. Koga, Y. Maitani, NaCl
induced high cationic hydroxyethylated
cholesterol-based nanoparticle-mediated synthetic siRNA transfer into prostate
carcinoma PC-3 cells, Biological & Pharmaceutical Bulletin, 31: 2294-2301 (2008). [Pubmed]
(45) A. Yamada, Y. Taniguchi, K. Kawano, T. Honda,
Y. Hattori, Y. Maitani, Design of
folate-linked liposomal doxorubicin to its antitumor effect in mice, Clinical Cancer Research, 14 (24): 8161-8168(2008). [Pubmed]
(44) Y.
Hattori*,
A Hagiwara, W. Ding and Y. Maitani, NaCl improves siRNA delivery mediated by
nanoparticles of hydroxyethylated cationic
cholesterol with amido-linker, Bioorganic
& Medicinal Chemistry letters, 18: 5228-5232 (2008). [Pubmed]
(43) T. Yoshizawa, Y. Hattor*,
M. Hakoshima, K. Koga and Y. Maitani, Folate-linked
lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts, European Journal of Pharmaceutics and
Biopharmaceutics, 70:
718-725 (2008). [Pubmed]
(42) Y. Ohguchi, K. Kawano, Y.
Hattori, Y. Maitani, Selective delivery of
folate-PEG-linked nanoemulsion-loaded aclacinomycin
A to KB nasopharyngeal cells and xenograft: Effect of chain length
and amount of folate-PEG linker, Journal of Drug Targeting, 16(9):
660-667 (2008). [Pubmed]
(41) T. Fujita, M. Furuhata, Y.
Hattori, H. Kawakami, K. Toma, Y.
Maitani, High gene delivery in tumor by intratumoral injection of tetraarginine-PEG
lipid-coated protamine/DNA, Journal of Controlled Release,
129(2): 124-127 (2008). [Pubmed]
(40) M. Watanabe, K. Kawano, K.Toma, Y. Hattori,
Y. Maitani, In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial
lipid and human serum albumin, Journal of Controlled Release,
127(3):
231-238 (2008). [Pubmed]
(39) M. Furuhata, R. Danev, K. Nagayama, Y. Yamada, H. Kawakami,
K. Toma, Y. Hattori, Y. Maitani, Decaarginine-PEG-artificial lipid/DNA complex for gene
delivery: nanostructure and transfection efficiency, Journal of Nanoscience and Nanotechnology, 8: 2308-2315 (2008).
[Pubmed]
(38) W. Ding, Y. Hattori, Y. Maitani.
Hydroxyethylated cationic cholesterol derivatives in
liposome vectors promote gene expression in the lung. International Journal of Pharmaceutics, 354(1-2): 196-203 (2008). [Pubmed]
(37) A. Hayama, T. Yamamoto, M. Yokoyama, K. Kawano, Y.
Hattori, Y. Maitani. Polymeric micelles modified
by folate-PEG-lipid for targeted drug delivery to cancer cells in vitro. Journal of Nanoscience and Nanotechnology,
8:
3085-3090 (2008). [Pubmed]
(36) M. Furuhata, Y. Hattori
and Y. Maitani, Novel oligoarginine-linked PEG-lipid micelles for gene delivery, The Proceedings of Hoshi University, 50:
21-32 (2008).
(35) M. Fukushima, Y. Hattori, H. Tsukada, K. Koga, E.
Kajiwara, K. Kawano, T. Kobayashi, K. Kamata, Y. Maitani.
Adiponectin gene therapy of streptozotocin-induced diabetic mice using
hydrodynamic injection. Journal of Gene
Medicine, 9:
976-985 (2007). [Pubmed]
(34) H. Poerwono, Y.
Hattori, H, Kubo and K. Higashiyama, Structure modification of
andrographolide to improve its potency as anticancer, Indonesian Journal of Chemistry, 7: 202-207 (2007). [Link]
(33) Y. Hattori*, Y. Maitani, Low-molecular-weight polyethylenimine
enhanced gene transfer by cationic cholesterol-based nanoparticle vector, Biological & Pharmaceutical Bulletin,
30: 1773-1778 (2007). [Pubmed]
(32) Y. Maitani, S. Igarashi, M. Sato,
Y. Hattori, Cationic liposome (DC-Chol/DOPE＝1:2) and
a modified ethanol injection method to prepare liposomes, increased gene
expression, International Journal of
Pharmaceutics, 342: 33-39 (2007). [Pubmed]
(31) Y. Hattori*, W.
Ding, Y. Maitani, Highly efficient cationic hydroxyethylated cholesterol-based nanoparticle-mediated
gene transfer in vivo and in vitro in prostate carcinoma PC-3 cells, Journal of Controlled Release, 120:
122-130 (2007). [Pubmed]
(30) E. Kajikawa, K. Kawano, Y. Hattori, M. Fukushima, K.
Hayashi, Y. Maitani, Long-circulating liposome-encapsulated
ganciclovir enhances the efficacy of herpes simplex virus thymidine kinase
suicide gene therapy in mice bearing nasopharyngeal xenografts, Journal of Controlled Release, 120:
104-110 (2007). [Pubmed]
(29) Y. Hattori, M. Fukushima and Y. Maitani.
Non-viral delivery of connexin 43 gene with histone deacetylase inhibitor to
human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo
tumor growth, International Journal of
Oncology, 30: 1427- 1439 (2007). [Pubmed]
(28) Y. Hattori and Y. Maitani,
DNA/lipid complex incorporated with fibronectin to cell adhesion enhances
transfection efficiency in prostate cancer cells and xenografts. Biological & Pharmaceutical Bulletin,
30: 603-607 (2007). [Pubmed]
(27) M. Fukushima, Y. Hattori, T. Yoshizawa, Y. Maitani. Combination of non-viral connexin 43 gene therapy
and docetaxel inhibits the growth of human prostate cancer in mice. International Journal of Oncology, 30:
225-231 (2007). [Pubmed]
(26) Y.
Hattori and Y. Maitani,
Tumor-targeting non-viral gene therapy for the treatment of oral
cancer, Oral Cancer Research Advances, edited by Alexios P. Nikolakakos, Nova Science Publishers, Inc., 95-124 (2007). [Link]
(25) Y. Maitani, S. Yano, Y.
Hattori, M. Furuhata, Y. Hayashi, Liposome vector containing
biosurfactant-complexed DNA as herpes simplex virus thymidine kinase gene
delivery system. Journal of Liposome
Research, 16: 359-372 (2006). [Pubmed]
(24) M. Furuhata, H. Kawakami, K. Toma, Y. Hattori, Y. Maitani, Intracellular delivery of proteins in complexes
with oligo-arginine modified liposomes, and the effect of oligo-arginine
length, Bioconjugate Chemistry, 17: 935-942 (2006). [Pubmed]
(23) Y. Hiruta, Y. Hattori, K. Kawano, Y. Obata, Y. Maitani, Novel ultra-deformable vesicles entrapped with
bleomycin and enhanced to penetrate rat skin, Journal of Controlled Release. 113: 146-154 (2006). [Pubmed]
(22) Y. Hattori, M. Sakaguchi and Y. Maitani,
Folate-linked lipid-based nanoparticles deliver a NFkB decoy into activated murine
macrophage-like RAW264.7 cells, Biological
& Pharmaceutical Bulletin, 29: 1516-1520, (2006). [Pubmed]
(21) Y. Hattori and Y. Maitani,
Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate
cancer, Cancer Science, 97: 787-798
(2006). [Pubmed]
(20) S. Igarashi, Y. Hattori, Y. Maitani,
Biosurfactant MEL-A enhances cellular association and gene transfection by
cationic liposome. Journal of Controlled
Release, 112: 362-368 (2006). [Pubmed]
(19) M. Furuhata, H. Kawakami, K. Toma, Y. Hattori, Y. Maitani, Design, synthesis and gene delivery efficiency of
novel oligo-arginine linked PEG-lipids: effect of oligo-arginine length. International Journal of Pharmaceutics,
316(1-2): 109-116, 2006. [Pubmed]
(18) Y. Hattori, H. Kubo, K. Higashiyama and Y. Maitani, Folate-linked nanoparticles formed with DNA
complexes in sodium chloride solution enhance transfection efficiency, Journal of Biomedical Nanotechnology,
1(2): 176-184 (2005). [Link]
(17) K.G. Lau, Y. Hattori, S. Chopra, E.A. O'Toole, A. Storey, T. Nagai and Y. Maitani,
Ultra-deformable liposomes containing bleomycin: In vitro stability and
toxicity on human cutaneous keratinocyte cell lines, International Journal of Pharmaceutics, 300: 4-12 (2005). [Pubmed]
(16) Y. Hattori and Y. Maitani,
Folate-linked nanoparticle-mediated suicide gene therapy in human prostate
cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase, Cancer Gene Therapy, 12: 796-809
(2005). [Pubmed]
(15) T. Shiokawa, Y. Hattori, K. Kawano, Y. Ouguchi, H. Kawakami, K. Toma, and Y. Maitani,
Effect of the PEG-linker Chain Length of Folate-linked Microemulsions Loading Aclacinomycin A on Targeting Ability and Antitumor Effect
in vitro and in vivo, Clinical Cancer
Research, 11(5): 2018-2025 (2005). [Pubmed]
(14) Y. Hattori and Y. Maitani,
Folate-linked lipid-based nanoparticle for targeted gene delivery, Current Drug Delivery, 2: 243-252
(2005). [Pubmed]
(13) M. Furuhata, H. Kawakami, K. Toma, Y. Hattori and Y.
Maitani, Design, Synthesis and Gene Delivery
Efficiencies of Novel oligo-Arginine Linked PEG-Lipid: Effect of Oligo-Arginine
Length, Peptide Science 2004,
241-242 (2005).
(12) Y. Hattori, Cancer gene delivery with folate
receptor targeting lipid-based nanoparticle. The Proceedings of Hoshi University, 47: 119-129 (2005). [Link]
(11) Y. Hattori and Y. Maitani,
Folate-linked Lipid-based Nanoparticles for Tumor-targeted Gene Therapy, Nanotechnologies
for the Life Science, Biofunctionalization of
nanomaterials, edited by Challa. Kumar,
Wiley-VCH, 1: 270-298 (2005). [Link]
(10) T. Fan, K. Takayama, Y. Hattori and Y. Maitani, Formulation Optimization of Paclitaxel Carried by
Pegylated Emulsions Based on Artificial Neural Network, Pharmaceutical Research, 21(9): 1694-1699 (2004). [Pubmed]
(9) Y. Hattori and Y. Maitani,
Enhanced in vitro transfection efficiency by novel folate-linked nanoparticles
in human prostate cancer and oral cancer, Journal
of Controlled Release, 97(1): 173-183 (2004). [Pubmed]
(8) T. Nagamoto, Y. Hattori, K.
Takayama and Y. Maitani, Novel Chitosan Particles and
Chitosan-Coated Emulsions Inducing Immune Response via Intranasal Vaccine
Delivery, Pharmaceutical Research,
21(4): 671-674 (2004). [Pubmed]
(7) K. Moriyama, J. Okuda, M. Saijo, Y. Hattori, N. Kanamoto, Y. Hataya, F. Matsuda, T. Mori, K. Nakao and T.
Akamizu, Recombinant monoclonal thyrotropin-stimulation blocking antibody (TSBAb) established from peripheral lymphocytes of a
hypothyroid patient with primary myxedema, Journal
of Endocrinological Investigation, 26(11): 1076-1080 (2003). [Pubmed]
(6) T. Akamizu, S. Ozaki, H. Hiratani, H. Uesugi, J. Sobajima, Y. Hataya, N. Kanamoto,
M. Saijo, Y. Hattori, K. Moriyama, K. Ohmori
and K. Nakao, Drug-induced neutropenia associated with anti-neutrophil
cytoplasmic antibodies (ANCA): possible involvement of complement in
granulocyte cytotoxicity, Clinical and
Experimental Immunology, 127(1):92-98 (2002). [Pubmed]
(5) Y. Hattori, T. Akamizu, M. Saijo, N. Kanamoto, K. Moriyama, N. Ito and K. Nakao,
Characterization of the secretable ectodomain of
thyrotropin receptor produced by the recombinant baculovirus system,. Molecular and Cellular Endocrinology,
182(2): 165-174 (2001). [Pubmed]
(4) Y. Hattori, A. Miyake, T. Mikami, M. Ohta and N.
Itoh, Transient expression of FGF-5 mRNA in the rat cerebellar cortex during
post-natal development, Molecular Brain
Research, 47(1-2): 262-266 (1997). [Pubmed]
(3) Y. Hattori, M. Yamasaki, M. Konishi and N. Itoh,
Spatially restricted expression of fibroblast growth factor-10 mRNA in the rat
brain, Molecular Brain Research,
47(1-2): 139-146 (1997). [Pubmed]
(2) A. Miyake, Y. Hattori, M. Ohta and N. Itoh, Rat
oligodendrocytes and astrocytes preferentially express fibroblast growth factor
receptor-2 and -3 mRNAs, Journal of
Neuroscience Research, 45(5): 534-541 (1996). [Pubmed]
(1) Y. Hattori, M. Yamasaki and N. Itoh, The rat FGF-5
mRNA variant generated by alternative splicing encodes a novel truncated form
of FGF-5, Biochimica et Biophysica
Acta, 1306(1): 31-33 (1996). [Pubmed]